Drug Profile
DWJ 208
Alternative Names: DWJ208Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Daewoong Pharmaceutical
- Class Analgesics
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer pain; Neuropathic pain
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Cancer-pain in South Korea
- 28 Dec 2021 No recent reports of development identified for phase-I development in Neuropathic-pain in South Korea
- 23 Nov 2018 Phase-I clinical trials in Cancer pain in South Korea (unspecified route) (Daewoong Pharmaceutical pipeline, November 2018)